ADTRAN
2.5.2024 14:01:30 CEST | Business Wire | Press release
Adtran today announced that a leading Canadian hydropower producer is using its Oscilloquartz grandmaster device combined with its optical cesium atomic clock to achieve new levels of precision, reliability and resilience in its power grid synchronization network. The deployment addresses the urgent need to implement the highest standards of protection against GNSS disruptions, including jamming and spoofing cyberattacks, and helps bolster North America’s energy resilience. Featuring multi-source protection, the enhanced timing architecture offers a zero-trust approach to positioning, navigation and timing (PNT), ensuring robust and accurate synchronization. It also seamlessly supports existing services, enabling a smooth transition from legacy timing to power grids with advanced PTP technology. For streamlined operations and assurance, the synchronization network is remotely managed through the Adtran Ensemble Controller with Sync Director.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240502346533/en/
Adtran’s Oscilloquartz timing technology is playing a key role in protecting Canadian hydropower producer from GNSS cyberattacks. (Photo: Business Wire)
“It’s great to be helping another major utility to modernize its timing infrastructure and prepare for next-generation smart grid applications. The transition from traditional TDM to advanced packet-based synchronization marks a significant milestone for this forward-thinking power supplier. The solution will also strengthen its timing network against the growing dangers of relying solely on GNSS,” commented John Scherzinger, GM of Americas sales at Adtran. “The deployment of our advanced grandmaster clock enables the utility to extend reliable timing to Canada’s most remote regions. The superior stability and precision of our optical cesium clock are key to realizing levels of accuracy and resilience never seen before. What’s more, our Ensemble Sync Director system brings the benefits of centralized control, ensuring comprehensive monitoring and simplified operational management. This is essential for maintaining the reliability and security of the utility’s extensive and often remotely located network.”
By enhancing its timing framework with Adtran’s Oscilloquartz solution, the hydroelectric producer is ensuring it maintains the highest standards of cybersecurity and energy reliability in its critical infrastructure. The deployment will also improve the stability and security of the energy supply across Canada and the US. The new solution includes Adtran’s OSA 3350 ePRC+ combined with its highly versatile OSA 5422 to provide the highest precision, stability and resilience against GNSS vulnerabilities. Featuring an all-digital design, the OSA 3350 ePRC+ utilizes optical-pumping techniques, guaranteeing timing accuracy and optimal stability for over a decade – twice the lifespan of conventional cesium clocks. Together with the OSA 5422, the solution future-proofs the utility’s timing network and assures compliance with governmental regulations. It also fortifies security and underscores the renewable energy utility’s commitment to maintaining a continuous, secure power supply.
“This leading Canadian power supplier is renowned for its dedication to innovation. Its choice to adopt our technology highlights both the impact of our solution and its significance on a global scale. By transitioning its substation network from traditional TDM to advanced packet-based synchronization, it’s setting a precedent for the entire industry to follow,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our solution offers robust defense against GNSS vulnerabilities and ensures adherence to stringent industry regulations. Through our ongoing support, the utility is reinforcing its dedication to enhancing both resilience and reliability – elements that are fundamental for fulfilling PNT requirements. This is crucial for safeguarding the integrity of critical network infrastructure, ensuring a consistent and dependable energy future for all.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502346533/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
